行情

AEZS

AEZS

依特钠
NASDAQ

实时行情|Nasdaq Last Sale

0.6026
-0.0230
-3.68%
盘后: 0.6030 +0.0004 +0.07% 19:46 09/24 EDT
开盘
0.6300
昨收
0.6256
最高
0.6380
最低
0.6016
成交量
50.30万
成交额
--
52周最高
3.620
52周最低
0.2900
市值
7,308.92万
市盈率(TTM)
-8.2543
分时
5日
1月
3月
1年
5年
Aeterna Zentaris 将出席 HC Wainwright 第 23 届年度全球投资大会
CHARLESTON, S.C., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, t...
GlobeNewswire · 09/08 12:00
BRIEF-Aeterna Zentaris Provides Pipeline Program Updates
reuters.com · 08/04 21:43
Aeterna Zentaris 报告 2021 年第二季度财务业绩并提供管道计划更新
– Company continues to advance clinical and preclinical programs with its diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need – Strong balance sheet with current cash of approximately $70 milli...
GlobeNewswire · 08/04 20:05
Aeterna Zentaris 收到纳斯达克关于最低出价合规性的通知;对上市没有直接影响
CHARLESTON, S.C., July 29, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic...
GlobeNewswire · 07/29 12:05
我们认为 Aeterna Zentaris (TSE:AEZS) 可以轻松推动业务增长
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Simply Wall St. · 06/28 05:56
对冲基金正在收购 AEterna Zentaris Inc. (AEZS)
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in re...
Insider Monkey · 06/13 18:10
中午市场更新:United Natural Foods 销量下滑; Aethlon Medical 股价上涨
Midway through trading Wednesday, the Dow traded up 0.09% to 34,631.35 while the NASDAQ rose 0.29% to 13,964.96. The S&P also rose, gaining 0.15% to 4,233.76.
Benzinga · 06/09 16:24
Aeterna Zentaris开始对Macimorelin进行肌萎缩性侧索硬化的动物研究
Benzinga · 05/17 14:12
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解AEZS最新的财务预测,通过AEZS每股收益,每股净资产,每股现金流等数据分析依特钠近期的经营情况,然后做出明智的投资选择。
分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测AEZS价格均价为4.500,最高价位4.500,最低价为4.500。
EPS
机构持股
总机构数: 47
机构持股: 221.26万
持股比例: 1.82%
总股本: 1.21亿
类型机构数股数
增持
6
10.21万
建仓
8
64.55万
减持
9
62.13万
平仓
6
16.13万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-2.13%
制药与医学研究
-1.02%
高管信息
Non-Executive Chairman/Independent Director
Carolyn Egbert
President/Chief Executive Officer/Director
Klaus Paulini
Chief Financial Officer/Senior Vice President
Leslie Auld
Senior Vice President/Managing Director
Eckhard Gunther
Senior Vice President
Nicola Ammer
Vice President - Finance
Guenther Grau
Vice President
Matthias Gerlach
Director
Dennis Turpin
Independent Director
Pierre-Yves Desbiens
Independent Director
Peter Edwards
Independent Director
Gilles Gagnon
暂无数据
AEZS 简况
Aeterna Zentaris Inc是一家专业的生物制药公司。该公司专注于开发和商业化多元化的医药和诊断产品组合,专注于重点未满足的医疗需求领域。其业务战略是完成Macrilen(macimorelin)产品的开发、制造、注册和商业化。Macrilen (macimorelin) 是一种可口服的肽胃饥饿素受体激动剂,通过与胃饥饿素受体(GHSR-1a)结合来刺激生长激素的分泌,并且在内分泌学和肿瘤学适应症中具有潜在作用。Macimorelin是用于诊断成人生长激素缺乏症(AGHD)的口服测试。该公司正在与Novo Nordisk合作,利用macimorelin的在临床和可靠的安全性来推进儿童期生长激素缺乏症(CGHD)的诊断。

微牛提供AEterna Zentaris Inc. (USA)(NASDAQ-AEZS)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的AEZS股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易AEZS股票基本功能。